Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET

Company Participants

Alex Lobo - Stern IR

Milton Werner - President & CEO

Joseph Frattaroli - CFO

Conference Call Participants

Edward White - H.C. Wainwright

Operator

Good morning and welcome to the Inhibikase Therapeutics First Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Alexander Lobo with Stern Investor Relations. Please go ahead.

Alex Lobo

Thank you. Good morning, everyone. With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer. On Monday, May 15, 2023, Inhibikase issued a press release announcing financial results for the first quarter ended March 31, 2023. We encourage everyone to read yesterday’s press release, as well as Inhibikase's annual – quarterly report on Form 10-Q which has been filed with the SEC. The company's press release and quarterly report are also available on Inhibikase's website at inhibikase.com.

In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time sensitive information that is accurate only as of the date of this live broadcast, May 16, 2023.

Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this live webcast, except as may be required by applicable securities law.

With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you may go ahead.

Milton Werner

Thank you, Alex, and thanks to everyone for joining us today for Inhibikase Therapeutics first quarter 2023 earnings call. Our focus heading into 2023 is to execute against our portfolio of neurodegenerative and oncology programs. Throughout the first quarter, we continued to validate our lead IkT-148009 program in Parkinson's disease, at multiple industry conferences, including the annual AD/PD conference, where we highlighted the data generated to date in our IkT-148009 program to potentially slow or halt the progression of Parkinson's disease.